Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Anbio Biotechnology Proxy Solicitation & Information Statement 2026

Apr 27, 2026

31914_ffr_2026-04-27_229e390e-6584-41a4-b409-802557e04d42.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

6-K 1 anbio6k042226.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 6-K

Field: Rule-Page

Field: /Rule-Page

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-42526

Anbio Biotechnology

Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany +49 69870039170

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

In connection with the extraordinary general meeting of shareholders of Anbio Biotechnology (the “Company”), attached hereto and incorporated by reference herein are Notice of Meetings of Shareholders and Proxy Statement and Form of Proxy Card.

Field: Page; Sequence: 2; Options: NewSection; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

EXHIBIT INDEX

Exhibit No. Description
99.1 Notice of Meetings of Shareholders and Proxy Statement
99.2 Form of Proxy Card for the Meeting of Shareholders
of Class A Ordinary Shares
99.3 Form of Proxy Card for the Meeting of Shareholders
of Class A Ordinary Shares and Class B Ordinary Shares
99.4 Amended and Restated Memorandum and Articles of Association

Field: Page; Sequence: 3; Value: 1

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Anbio Biotechnology — By: | /s/
Michael Lau |
| --- | --- |
| Name: | Michael Lau |
| Title: | Chief Executive Officer |

Field: Page; Sequence: 4; Options: Last

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page